<DOC>
	<DOCNO>NCT02029716</DOCNO>
	<brief_summary>This study first-in-human study topical dermal lotion formulation RTA 408 , novel small molecule suppresses oxidative stress inflammation . In study , safety , local pharmacodynamics ( PD ) , systemic pharmacokinetics ( PK ) RTA 408 evaluate follow topical application RTA 408 Lotion healthy volunteer . This study conduct three part . In Part A study , healthy volunteer RTA 408 Lotion Vehicle RTA 408 Lotion ( 0.5 % , 1 % , 3 % ) apply small skin surface area ( four individual 4-cm2 site ; 16 cm2 total area ) twice daily 14 day assess local skin tolerability , local PD , systemic PK treatment . Part B conduct completion Part A ass safety , tolerability , local PD , systemic PK RTA 408 Lotion apply topically twice daily 14 day large skin surface area ( ~100 cm2 ) . Part C conduct completion Part B ass safety , tolerability , local PD , systemic PK RTA 408 Lotion apply topically twice daily 28 day large skin surface area ( ~500 cm2 ) . The maximum tolerated drug concentration Part A used Part B Part C. Approximately 32 healthy adult volunteer enrol study 12 volunteer Part A 10 volunteer , Parts B C .</brief_summary>
	<brief_title>RTA 408 Lotion Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>1 . Subjects must voluntarily give write informed consent agree comply visit schedule include willingness remain study site ; 2 . Subjects must adults ( male female ) , age 18 65 , inclusive ; 3 . Subjects must healthy skin redden easily recognize ( Fitzpatrick type IIV skin ) ; 4 . The planned application site must unbroken skin ( ie , free cut , scratch , abrasion ) , free excessive hair , tattoo , abnormality , Investigator 's judgement , would interfere conduct study ; 5 . Subjects must body mass index ( BMI ) ≥18 kg/m2 ≤32 kg/m2 ; 6 . Women must nonchildbearing potential may pregnant , lactate , breastfeed . 7 . Male subject must agree female partner use 2 acceptable form contraception , 1 must condom , 3 month last dose study drug . 1 . Persons Fitzpatrick skin type V VI ; 2 . Presence active inflammatory dermatosis ( eg , atopic dermatitis , psoriasis ) , bacterial , viral , fungal skin infection ; 3 . History clinically significant drug allergy include allergy component investigational product and/or clinically significant food allergy determine Investigator ; 4 . Use alcohol methylxanthinecontaining beverage food ( eg , coffee , tea , cola , chocolate , `` power drink '' ) 72 hour prior first dose study drug last protocol specify blood sample ; 5 . Use tobacco product , nicotinecontaining product , pharmacologic smoke cessation therapy 3 month immediately prior first dose study drug , and/or willing able refrain use product duration study last protocol specify blood sample ; 6 . History alcohol abuse within 2 year Screening Visit , judgment Investigator , average weekly alcohol consumption &gt; 14 alcoholic drink . One drink define 1 glass beer ( approximately 10 oz 12 oz ) 1 ( 12 oz ) beer , 1 glass wine ( approximately 4 oz 5 oz ) , 1 glass distil spirit ( hard liquor ) contain 1 oz liquor ( 1 oz liquid approximately 30 mL ) ; 7 . Positive breath test alcohol Screening Visit Day 1 ; 8 . History drug abuse within 2 year Screening Visit , judgment Investigator ; 9 . Positive urine test cotinine drug abuse ( ie , opiate , methadone , cocaine , amphetamine , cannabinoids , barbiturate , benzodiazepine ) Screening Visit Day 1 ; 10 . Not willing abstain strenuous exercise ( eg , heavy lifting , weight training , calisthenics , aerobics ) least 48 hour prior admission investigational site last protocol specify blood sample ; 11 . Use substance know strong inhibitor inducer Cytochrome P450 ( CYP450 ) enzymes ( eg , ritonavir , ketoconazole , nefazodone , grapefruit juice ) within 14 day prior first dose study drug last study visit . Chronic exposure enzyme inducer paint solvent pesticide investigational drug use within 30 day prior study drug administration ; 12 . Use prescription drug , dietary supplement , herbal remedy ( include product apply topically ) within 14 day 5 halflives ( whichever longer ) prior first dose study drug ; use nonprescription drug vitamin ( include product apply topically ) within 7 day prior first dose study drug ; unwillingness refrain take medication last protocol specify blood sample ; 13 . Donation whole blood &gt; 450 mL blood product within 56 day prior admission investigational site ; 14 . Use investigational drug within 30 day 5 halflives previous investigational drug prior first dose study drug study , whichever longer ; 15 . Positive screen human immunodeficiency virus ( HIV ) , hepatitis B , and/or hepatitis C Screening Visit ; 16 . Acute illness accompany temperature ≥101○F within 5 day prior study drug administration ; 17 . Presence history cancer within 5 year prior Screening Visit ( basal cell skin cancer location back without active lesion adequately treat carcinoma situ cervix ) ; 18 . Presence history significant cardiovascular , gastrointestinal , hepatic , renal , pulmonary , hematologic , endocrine , immunologic , dermatologic , neurologic disease 19 . Presence condition ( include surgery ) know interfere absorption , distribution , metabolism , excretion medicine . History appendectomy cholecystectomy permit ; 20 . Any abnormal clinical laboratory value abnormal electrocardiogram ( ECG ) find Screening Visit Day 1 consider clinically significant Investigator ; 21. International Normalized Ratio ( INR ) &gt; 1.5 Screening Visit ; 22 . Men whose female partner pregnant lactating , plan become pregnant study within 3 month end study ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>RTA 408</keyword>
	<keyword>RTA 408 Lotion</keyword>
	<keyword>Oxidative stress</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Volunteers</keyword>
</DOC>